Gene 'driver' of Waldenstrom's Macroglobulinemia in up to one-third of patients identified

(Dana-Farber Cancer Institute) In nearly one-third of patients with Waldenstrom's Macroglobulinemia, a specific genetic mutation switches on the disease, and a new drug that blocks the defective gene can arrest the disease in animal models, researchers at Dana-Farber Cancer Institute and allied institutions will report at the 2013 annual meeting of the American Society of Hematology. The finding may open the way to clinical trials of the drug in Waldenstrom's patients whose tumor cells carry the mutation.

http://www.eurekalert.org/pub_releases/2013-12/dci-go120513.php

Source: EurekAlert! - Medicine and Health - December 9, 2013 Category: Global & Universal Source Type: news